You are now leaving www.klisyrihcp.com
You are now leaving KlisyriHCP.com and will be directed to an independent, third-party website. The Privacy Policy and the Terms of Use of the destination website will apply.
Quick Links
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Although KLISYRI® is a treatment regimen for only 5 days, topical AK treatments still take time
Let patients know that, with KLISYRI®, complete AK clearance was achieved in a majority of patients at day 571
See more study results for KLISYRI®
Although KLISYRI® is a treatment regimen for only 5 days, topical AK treatments still take time
Let patients know that, with KLISYRI®, complete AK clearance was achieved in a majority of patients at day 571
See more study results for KLISYRI®
Topical treatments are often associated with local skin reactions and other adverse events, and may take several days or weeks to resolve2
Let patients know that the most common side effects of KLISYRI® included itching or pain in the treatment area1
See more about the safety and tolerability of KLISYRI®
Topical treatments are often associated with local skin reactions and other adverse events, and may take several days or weeks to resolve2
Let patients know that the most common side effects of KLISYRI® included itching or pain in the treatment area1
See more about the safety and tolerability of KLISYRI®
Tell patients that KLISYRI® is the shortest topical Rx treatment for AK available today, and that KLISYRI® SHOULD be used for only 5 consecutive days1
If you are giving patients a starter sample, instruct them to use the sample only if they are picking up their full 5-day prescription the very next day
Because KLISYRI® prescription packs contain 5 packets of medication, patients who receive a starter sample will have an extra packet and SHOULD be told to use 5 packets ONLY
PLEASE NOTE: the KLISYRI® prescription pack contains 5 packets of medication. Patients who receive a sample packet may inadvertently use a total of 6 packets instead of the prescribed 5. Please advise patients to use a total of 5 packets for 5 consecutive days.
Tell patients that KLISYRI® is the shortest topical Rx treatment for AK available today, and that KLISYRI® SHOULD be used for only 5 consecutive days1
If you are giving patients a starter sample, instruct them to use the sample only if they are picking up their full 5-day prescription the very next day
Because KLISYRI® prescription packs contain 5 packets of medication, patients who receive a starter sample will have an extra packet and SHOULD be told to use 5 packets ONLY
PLEASE NOTE: the KLISYRI® prescription pack contains 5 packets of medication. Patients who receive a sample packet may inadvertently use a total of 6 packets instead of the prescribed 5. Please advise patients to use a total of 5 packets for 5 consecutive days.
Savings and support can help ensure patients fill and continue to take their prescription2
Let patients know that KLISYRI® offers cost savings and support for eligible patients*
Check with your KLISYRI® network specialty pharmacy to compare out-of-pocket costs
See more about patient savings through Almirall Advantage
Savings and support can help ensure patients fill and continue to take their prescription2
Let patients know that KLISYRI® offers cost savings and support for eligible patients*
Check with your KLISYRI® network specialty pharmacy to compare out-of-pocket costs
See more about patient savings through Almirall Advantage
*
Eligible patients with commercial (nongovernmental) insurance only.
Terms and conditions may apply.
AK: actinic keratosis.
Important Safety Information
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com
Important Safety Information
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com
References:
1. KLISYRI® [package insert]. Malvern, PA: Almirall, LLC, 2021. 2. Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017;32(suppl 2):17-20.
This site is intended for US audiences only.
KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2023. All Rights Reserved. Almirall, LLC, 101 Lindenwood Drive, Suite 200, Malvern, PA 19355 US-TIRBA-2300013 03/2023
Qualified U.S. healthcare professionals who are practicing medicine in the U.S. are invited to register, should they wish to receive information about KLISYRI®.
KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2023. All Rights Reserved. Almirall, LLC, 101 Lindenwood Drive, Suite 200, Malvern, PA 19355 US-TIRBA-2300013 03/2023
Get Updates
Full Prescribing Information
